Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Novel cyclin-dependent kinase 4 (Cdk4) inhibitors as potential anticancer agents

Joshi, K.S., Rathos, M., Mahajan, P., Wagh, V., Shenoy, S., Lai, B., Mascarenhas, M., Kamble, S., Kulkarni, S., and Totre, J. Novel cyclin-dependent kinase 4 (Cdk4) inhibitors as potential anticancer agents. Clin Cancer Res. 2003; (9):6222.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.